PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(02): 111-117
DOI: 10.4103/wjnm.WJNM_36_19
Original Article

18F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting overall survival of oral cavity squamous cell carcinoma: Ongoing controversy

Stephen Scott
1   Wellstar Atlanta Medical Center, Family Medicine, Atlanta
2   Department of Radiology, Augusta University, Augusta
,
J Byrd
3   Department of Otolaryngology, Augusta University, Augusta
,
Ramon Figueroa
2   Department of Radiology, Augusta University, Augusta
,
Hadyn Williams
2   Department of Radiology, Augusta University, Augusta
,
Jie Chen
4   Population Health Sciences, Augusta University, Augusta
,
Jaeeun Lee
4   Population Health Sciences, Augusta University, Augusta
,
Darko Pucar
2   Department of Radiology, Augusta University, Augusta
5   Department of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, USA
› Author Affiliations
› Further Information
Also available ateRefMedOne
  Permissions and Reprints
Preview

Abstract

We aimed to retrospectively determine if initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) can predict overall survival (OS) in oral cavity squamous cell carcinoma (OCSCC), which is currently a source of ongoing controversy in the literature. Forty-six consecutive patients with nonmetastatic (Stage M0) OCSCC had 18F-FDG PET/CT prior to definitive surgical treatment followed by observation or adjuvant treatment at our institution between 2006 and 2012. The median follow-up time was 18 months (range 0.1–76 months). Univariate and multivariate analysis were used to determine the ability of imaging, pathologic, and demographic factors to predict OS. 18F-FDG PET/CT parameters were standardized uptake value (SUV) maximum and mean, metabolic tumor volume, and total lesional glycolysis (TLG) of primary tumor and regional nodes. Significant predictors of OS in the multivariate analysis were primary tumor SUV mean, nodal TLG, and age. Two-year OS of patients with primary tumor SUV mean below and above the median of 6.26 was 68% and estimated 28%, respectively. Two-year OS of patients with nodal TLG below and above median of 7.9 was 69% and 34%, respectively. Two-year OS of patients younger and older than median age of 57 was 60% and 43%, respectively. Our results suggest that 18F-FDG PET/CT may be a valuable addition to multifactorial models predicting outcome for OCSCC. Thus, continued research aiming to incorporate 18F-FDG PET/CT parameters in risk-stratification algorithms for OCSCC is warranted and should be conducted using more standardized prognostic models driven by a specific clinical question.

Keywords

Fluorodeoxyglucose - oral cavity squamous cell carcinoma - overall survival - positron emission tomography

Financial support and sponsorship

Nil.




Publication History

Received: 07 March 2019

Accepted: 27 June 2019

Article published online:
19 April 2022

© 2020. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
  • 2 Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988;48:3282-7.
  • 3 Pfister D, Spencer S, Adelstein D, Adksins D, Brizel DM, Burtness B, et al. National Comprehensive Cancer Network Practice Guideliness in Oncology. Head and Neck Cancers Version 1; 2018. Available from: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. [Last accessed on 2019 Jun 13].
  • 4 Luryi AL, Chen MM, Mehra S, Roman SA, Sosa JA, Judson BL, et al. Treatment factors associated with survival in early-stage oral cavity cancer: Analysis of 6830 cases from the national cancer data base. JAMA Otolaryngol Head Neck Surg 2015;141:593-8.
  • 5 Rusthoven K, Ballonoff A, Raben D, Chen C. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer 2008;112:345-51.
  • 6 Kao J, Vu HL, Genden EM, Mocherla B, Park EE, Packer S, et al. The diagnostic and prognostic utility of positron emission tomography/computed tomography-based follow-up after radiotherapy for head and neck cancer. Cancer 2009;115:4586-94.
  • 7 Kim JW, Roh JL, Kim JS, Lee JH, Cho KJ, Choi SH, et al. (18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma. Br J Cancer 2013;109:2973-9.
  • 8 Sheikhbahaei S, Taghipour M, Ahmad R, Fakhry C, Kiess AP, Chung CH, et al. Diagnostic accuracy of follow-up FDG PET or PET/CT in patients with head and neck cancer after definitive treatment: A systematic review and meta-analysis. AJR Am J Roentgenol 2015;205:629-39.
  • 9 Shintani SA, Foote RL, Lowe VJ, Brown PD, Garces YI, Kasperbauer JL, et al. Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys 2008;70:322-9.
  • 10 Abd El-Hafez YG, Chen CC, Ng SH, Lin CY, Wang HM, Chan SC, et al. Comparison of PET/CT and MRI for the detection of bone marrow invasion in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 2011;47:288-95.
  • 11 Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM, et al. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: Adding value to clinical staging. J Nucl Med 2012;53:709-15.
  • 12 Hofele C, Freier K, Thiele OC, Haberkorn U, Buchmann I. High 2-[18F] fluoro-2-deoxy-d-glucose (18FDG) uptake measured by positron emission tomography is associated with reduced overall survival in patients with oral squamous cell carcinoma. Oral Oncol 2009;45:963-7.
  • 13 Kendi AT, Corey A, Magliocca KR, Nickleach DC, Galt J, Switchenko JM, et al. 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers? Eur J Radiol 2015;84:1171-6.
  • 14 Kim M, Higuchi T, Nakajima T, Andriana P, Hirasawa H, Tokue A, et al. 18F-FDG and 18F-FAMT PET-derived metabolic parameters predict outcome of oral squamous cell carcinoma. Oral Radiol 2019. doi: 10.1007/s11282-019-00377-2. [Epub ahead of print].
  • 15 Ryu IS, Kim JS, Roh JL, Cho KJ, Choi SH, Nam SY, et al. Prognostic significance of preoperative metabolic tumour volume and total lesion glycolysis measured by (18)F-FDG PET/CT in squamous cell carcinoma of the oral cavity. Eur J Nucl Med Mol Imaging 2014;41:452-61.
  • 16 Schwartz DL, Harris J, Yao M, Rosenthal DI, Opanowski A, Levering A, et al. Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: Pilot results from radiation therapy oncology group protocol 0522. Int J Radiat Oncol Biol Phys 2015;91:721-9.
  • 17 Romesser PB, Lim R, Spratt DE, Setton J, Riaz N, Lok B, et al. The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positron emission tomography scan. Oral Oncol 2014;50:802-8.
  • 18 Alluri KC, Tahari AK, Wahl RL, Koch W, Chung CH, Subramaniam RM, et al. Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. AJR Am J Roentgenol 2014;203:897-903.
  • 19 Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. New York, Dordrecht, Heidelberg, London: Springer; 2010.
  • 20 Mücke T, Kanatas A, Ritschl LM, Koerdt S, Tannapfel A, Wolff KD, et al. Tumor thickness and risk of lymph node metastasis in patients with squamous cell carcinoma of the tongue. Oral Oncol 2016;53:80-4.
  • 21 Schwam ZG, Judson BL. Improved prognosis for patients with oral cavity squamous cell carcinoma: Analysis of the national cancer database 1998-2006. Oral Oncol 2016;52:45-51.